Integration of Clinical Criteria into the Training of Deep Models:
  Application to Glucose Prediction for Diabetic People by De Bois, Maxime et al.
1Integration of Clinical Criteria into the Training of
Deep Models: Application to Glucose Prediction for
Diabetic People
Maxime De Bois, Mounîm A. El Yacoubi, and Mehdi Ammi
Abstract—Standard objective functions used during the train-
ing of neural-network-based predictive models do not consider
clinical criteria, leading to models that are not necessarily
clinically acceptable. In this study, we look at this problem from
the perspective of the forecasting of future glucose values for
diabetic people. In this study, we propose the coherent mean
squared glycemic error (gcMSE) loss function. It penalizes the
model during its training not only of the prediction errors, but
also on the predicted variation errors which is important in
glucose prediction. Moreover, it makes possible to adjust the
weighting of the different areas in the error space to better focus
on dangerous regions. In order to use the loss function in practice,
we propose an algorithm that progressively improves the clinical
acceptability of the model, so that we can achieve the best tradeoff
possible between accuracy and given clinical criteria. We evaluate
the approaches using two diabetes datasets, one having type-1
patients and the other type-2 patients. The results show that using
the gcMSE loss function, instead of a standard MSE loss function,
improves the clinical acceptability of the models. In particular, the
improvements are significant in the hypoglycemia region. We also
show that this increased clinical acceptability comes at the cost of
a decrease in the average accuracy of the model. Finally, we show
that this tradeoff between accuracy and clinical acceptability can
be successfully addressed with the proposed algorithm. For given
clinical criteria, the algorithm can find the optimal solution that
maximizes the accuracy while at the same meeting the criteria.
Index Terms—deep learning, clinical acceptability, multi-
objective optimization, neural network, glucose prediction, di-
abetes
I. INTRODUCTION
With 4.2 million of imputed deaths in 2019, diabetes is
undoubtedly one of the major diseases of our modern world
[1]. Compared to healthy persons, diabetic people experience
trouble in the regulation of their blood glucose level. Whereas
pancreas of type-1 diabetic people do not produce insulin, a
hormone responsible for the absorption of glucose in the blood,
the body cells of type-2 diabetic patients get increasingly
resistant to its action. Failing to regulate the blood sugar level
put the patient at risk of getting in states of hypoglycemia
and hyperglycemia. In hypoglycemia (blood sugar level below
70 mg/dL) the patient faces short-term consequences such as
clumsiness, coma or even death. On the other hand, with
hyperglycemia (blood sugar level above 180 mg/dL), the
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consequences are more long-term with an increased risk of
cardiovascular diseases or blindness.
In the recent years, a lot of researchers have been inter-
ested in the creation of glucose predictive models [2]. Using
past glucose values, carbohydrate (CHO) intakes and insulin
infusions information, the models can forecast the future
glucose values 30 to 60 minutes ahead of time [2]. For the
diabetic patient, being able to know the future values of his/her
glycemia could be highly beneficial as hypo/hyperglycemia
could be anticipated. Historically, glucose predictive models
are based on autoregressive processes [3]. However, thanks
to the advance in machine learning and deep learning, but
also in the increased availability of data, we are currently
witnessing a shift in favor of more complex models, and
in particular models based on neural networks. The use of
standard feedforward neural networks has been explored with,
for instance, the works of Pappada et al. [4], Georga et al.
[5] and Ben Ali et al. [6]. Recurrent neural networks, and
in particular those based on long short-term memory (LSTM)
units, are probably the most popular deep models for glucose
prediction. Aliberti et al. showed that they are more accurate
than standard autoregressive models [7]. Mirshekarian et al.
demonstrated their superiority over support vector regression
(SVR) models that use expert physiological features [8]. They
also have been shown to benefit from the addition of various
input features such as heart rate or skin conductance [9],
[10]. Other neural-network-based solutions have been tried out
recently. Among them, we can highlight the promising use of
convolutional neural networks [11], [12].
Models based on neural networks are trained by backprop-
agating the gradient of the average error to the weights of
the network. In glucose prediction, as in almost all regression
problems, the average error is computed as the mean squared
error (MSE). As a consequence, the models are trained on
maximizing the accuracy of the predictions. However, in the
benchmark study we recently conducted [13], we showed that
a good accuracy does not ensure that the predictions are clin-
ically acceptable. Indeed, some errors, despite their relatively
low magnitude, can be very dangerous for the patient (e.g.,
errors in the hypoglycemia region). To address this issue, Del
Favero et al. proposed the gMSE loss function that amplifies
the weights of the errors based on the observed glycemic
region [14]. They showed that using the gMSE instead of the
standard MSE decreases the number of dangerous predictions
at the cost of reducing the average accuracy of the model.
While their methodology is promising, their study has several
2limitations that we aim at addressing. First, as the approach has
been evaluated using autoregressive models on virtual diabetic
patients, it is unclear how it translates to more complex models
and to real patients. Also, their approach focuses on only one
aspect of the clinical acceptability of the predictions, which
is the point clinical accuracy. Another aspect of the clinical
acceptability of the predictions is the clinical accuracy of
predicted variations (i.e., difference between two successive
predictions compared to the observed variations), which is
taken into account in the widely used continuous glucose-
error grid analysis (CG-EGA) metric [15]. Indeed, inaccurate
predicted glucose variations can be very dangerous as they can
confuse the patient in the understanding of the future evolution
of the glycemia.
Our contributions are:
1) We propose a new loss function called the coherent
mean squared glycemic error (gcMSE). Compared to
the standard MSE, it includes constaints directly related
to the clinical acceptability of the models. In particular,
it penalizes the model during its training not only on
prediction errors, but also on predicted variations errors
[16]. Moreover, it makes possible to increase the im-
portance of specific regions in the error space (e.g., the
hypoglycemia region).
2) The gcMSE faces a multi-objective optimization prob-
lem. Indeed, when promoting the learning of a model
focused more on making clinically acceptable predic-
tions, we reduce the constraints on its global accuracy.
However, for the model to be useful for the diabetic
patient, it needs to be accurate. To address this challenge,
we propose the PICA algorithm that iteratively relax
the accuracy constraints so that the focus is progres-
sively more in favor on the satisfaction of the clinical
constraints. This enables the creation of a model that
maximizes the accuracy while at the same time that
respects the given clinical constraints.
3) We evaluate the proposed solutions on two diabetes
datasets, the IDIAB dataset and the OhioT1DM dataset,
characterized by their heterogeneity. Whereas the IDIAB
dataset, collected by ourselves, is made of 6 type-
2 diabetic patients, the OhioT1DM dataset has been
released by Marling et al. and comprises data from 6
type-1 diabetic patients [17].
4) We open-sourced the code written in Python that has
been used in this study in a GitHub repository [18].
The paper is organized as follows. First, after introducing
the CG-EGA metric in more details, we present the whole
framework for its integration into the training of deep models.
Then, we describe the machine learning pipeline, with the
preprocessing of the data, the models we used, and the evalu-
ation process. Finaly, we present and discuss the experimental
results.
II. INTEGRATING CLINICAL CRITERIA INTO THE
TRAINING OF DEEP MODELS
In this section we propose a method to integrate the clinical
criteria of the CG-EGA within the training of deep models.
First, we introduce, in details, how the CG-EGA metric works.
Then, we present the gcMSE loss function that integrates the
clinical constraints. Finally, we propose a methodology to use
this new cost function in practice.
A. Presentation of the CG-EGA
Originally proposed by Kovatchev et al. for the evaluation
of the clinical acceptability of blood glucose sensors [15], the
continuous glucose-error grid analysis (CG-EGA) is a widely
used metric to assess the clinical acceptability of glucose
predictive models [2]. It is made of the combination of two
different evaluation grids: the point-error grid analysis (P-
EGA) and the rate-error grid analysis (R-EGA). While the
P-EGA measure the clinical accuracy of the predictions, the R-
EGA measures the clinical accuracy of the predicted variations.
The predicted variations are computed as the rate of change
between two consecutive predictions. Both grids attribute to a
given prediction a score from A (best) to E (worst) representing
the dangerousness of the prediction. Figure 1 gives a graphical
representation of both grids. The scores in both grids are then
combined into a final label assessing the clinical acceptability
of the metric. A prediction can either be an accurate prediction
(AP), a benign error (BE), or an erroneous prediction (EP).
Table I details the reasoning behind the CG-EGA scores.
First, the CG-EGA has a different behavior depending on
the glycemic region (hypoglycemia, euglycemia, or hyper-
glycemia). Essentially, the glycemic region impacts the way
bad R-EGA scores (C to E) are accounted. For instance, in the
hypoglycemia region, a lE score in the R-EGA, representing
a fast predicted decrease in glycemia while a fast increase is
observed, can lead to a benign error (BE) if the last prediction
is accurate (A in the P-EGA). In the hypoglycemia region,
the CG-EGA implies that it is not dangerous for the patient
to predict a decrease in glycemia as it will not lead to life-
threatening actions from the patient. On the other hand, the
absence of detection of negative variations in the uD and
uE zones is extremely dangerous: hypoglycemia is becoming
much worse, which could result in consequences such as coma
or even death. Overall, for a prediction to be labelled as an
accurate prediction AP, it needs good scores (A or B) in both
grids.
In summary, compared to standard accuracy metrics such as
the root mean squared error (RMSE), the CG-EGA also eval-
uates the accuracy of the predicted variations. And, most im-
portantly, these evaluations depend on the observed glycemic
region. These aspects should be taken into account if we want
to add clinical constraints based on the CG-EGA into the
training of the models.
B. Coherent Mean Squared Error
In deep learning, the models are trained by backpropagating
the gradient of the loss function to the networks’ weights.
Thus, by modifying the objective function, it is possible to
modify the predictive behavior of the model. We can find nu-
merous cost functions in the literature, the most used being the
cross-entropy for classification problems and the mean squared
error (MSE) for regression problems. Since glucose prediction
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Fig. 1: Example of the CG-EGA classification with the P-EGA (left) and R-EGA (right).
TABLE I: Classification of glucose predictions performed by the CG-EGA. Depending on the scores obtained on the P-EGA
and R-EGA, a prediction is classified as an accurate prediction (AP), a benign error (BE) or erroneous prediction (EP).
P-EGA
Hypoglycemia Euglycemia Hyperglycemia
A D E A B C A B C D E
R
-E
G
A
A AP EP EP AP AP EP AP AP EP EP EP
B AP EP EP AP AP EP AP AP EP EP EP
uC BE EP EP BE BE EP BE BE EP EP EP
lC BE EP EP BE BE EP BE BE EP EP EP
uD EP EP EP BE BE EP BE BE EP EP EP
lD BE EP EP BE BE EP EP EP EP EP EP
uE EP EP EP EP EP EP EP EP EP EP EP
lE BE EP EP EP EP EP EP EP EP EP EP
AP: Accurate Prediction; BE: Benign Error; EP: Erroneous Prediction
is a regression task, deep models in the field use the MSE in
the model’s training. Equation 1 describes MSE as the squared
difference between the observed g and predicted gˆ, averaged
over N samples. In this study, we propose modifications to the
MSE cost function to improve the clinical acceptability of the
predictions.
MSE(g, gˆ) =
1
N
N∑
n=1
(gn − gˆn)2 (1)
First, as we have seen by analyzing the CG-EGA behavior,
it is essential to penalize predicted variation errors in addition
to prediction errors. To do this, we can use the coherent
mean squared error (cMSE) loss function, previously proposed
in a work of ours [16]. The cMSE is the MSE of the
predictions weighted by the MSE of the predicted variations.
The Equation 2 describes the cMSE loss function with ∆g
and ∆gˆ representing, respectively, the observed and predicted
glucose variations. We call the weighting coefficient c the
coherence factor. It represents the relative importance we give
to the accuracy of the predicted variations versus the accuracy
of the predictions.
cMSE(g, gˆ) = MSE(g, gˆ) + c ·MSE(∆g,∆gˆ)
=
1
N
N∑
n=1
(gn − gˆn)2 + c · (∆gn −∆gˆn)2
(2)
To be able to use the cMSE, we can use a recurrent neural
network (e.g., LSTM) with two outputs (see Figure 2). The
two outputs represent the prediction at the given prediction
horizon PH and the prediction at PH −∆T , ∆T being the
time interval between two predictions. For instance, with a
prediction interval of 5 minutes and a prediction horizon of 30
minutes, the networks outputs the predictions at the horizons
30 and 25 minutes. These two outputs enables the computation
of the predicted variations, as depicted by Equation 3. The
architecture of recurrent neural networks is particularly suited
to this task since each sub-module of the unfolded network
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Fig. 2: General architecture of a two-output recurrent neural network that has been unrolled H times, where H is the length
of the history of input data to the model. Xt are the input data to the model at time t (e.g., glucose, insulin, and carbohydrates
at time t), and yˆt+PH is the model prediction (e.g., blood glucose prediction) at t+PH , where PH is the prediction horizon.
(see Figure 2) shares the same weights.
∆gˆt+PH =
gˆt+PH − gˆt+PH−∆T
∆T
(3)
C. Coherent Mean Squared Glycemic Error
The analysis of the CG-EGA showed us that glucose
prediction errors and predicted variation errors do not have
the same clinical importance in the error space (see Table
I). Although generally of greater magnitude, these clinical
errors are rare and represent only a small portion of the
gradient in the updating of the network’s weights during its
training. Therefore, minimizing the MSE (or, equivalently,
the cMSE) does not directly reduce the number of clinical
errors. Indeed, most of the weight updates are focused towards
the improvement of the accuracy of predictions that already
have good a clinical acceptability. In the field of multi-class
classification, it is very common to weight samples from under-
represented classes by artificially increasing their presence
within the training set. In their work on object recognition
within images, Lin et al. proposed to dynamically weight the
learning samples according to their difficulty (a sample being
considered easy when the probability of the corresponding
class is very high, showing a high degree of confidence in
the model) [19]. By reducing the weights of samples judged
easy, the training of the model focuses on the samples for
which it has the most difficulty. Finally, Del Favero et al.
proposed, in the context of glucose prediction, to modify the
MSE to better account for the dangerous regions of the P-EGA
[14]. In particular, they proposed that samples with observed
hypoglycemia or hyperglycemia should be given a higher
weighting. Although this work was evaluated on autoregressive
models and virtual patients, their results showed that this new
cost function reduces the number of predictions in zone D and
E of the P-EGA grid.
Taking inspiration from their work, we propose to
dynamically penalize prediction errors as well as pre-
dicted variation errors. This new cost function, named
coherent mean squared glycemic error (gcMSE), penal-
izes predictions differently depending on the P-EGA and
R-EGA regions (see Equation 4). In Equation 4b, PX
and px, X ∈ {A,B, uC, lC, uD, lD, uE, lE} and x ∈
{a, b, uC, lC, uD, ld, uE, le}, represent the P-EGA grid re-
gions and their respective weights. Contrary to the original
P-EGA, we have segmented the C, D and E regions in
two, as it is already the case for the R-EGA. This allows
more flexibility in assigning weights. Equivalently, in Equation
4c, RX and rx, X ∈ {A,B, uC, lC, uD, lD, uE, lE} and
x ∈ {a, b, uC, lC, uD, ld, uE, le} represent the regions of the
R-EGA grid and their respective weights.
gcMSE(g, gˆ) = P (g, gˆ) ·MSE(g, gˆ)
+ c ·R(∆g,∆gˆ) ·MSE(∆g,∆gˆ) (4)
with,
P (g, gˆ) =

pa, if {g, gˆ} ∈ PA
pb, if {g, gˆ} ∈ PB
puc, if {g, gˆ} ∈ PuC
plc, if {g, gˆ} ∈ PlC
pud, if {g, gˆ} ∈ PuD
pld, if {g, gˆ} ∈ PlD
pue, if {g, gˆ} ∈ PuE
ple, if {g, gˆ} ∈ PlE
(4b)
and,
R(∆g,∆gˆ) =

ra, if {∆g,∆gˆ} ∈ RA
rb, if {∆g,∆gˆ} ∈ RB
ruc, if {∆g,∆gˆ} ∈ RuC
rlc, if {∆g,∆gˆ} ∈ RlC
rud, if {∆g,∆gˆ} ∈ RuD
rld, if {∆g,∆gˆ} ∈ RlD
rue, if {∆g,∆gˆ} ∈ RuE
rle, if {∆g,∆gˆ} ∈ RlE
(4c)
Using the gcMSE instead of the standard MSE introduces
514 new hyperparameters to be optimized: the c coherence
factor, and the weights associated with the P-EGA and R-EGA
regions. This task being particularly laborious, we propose
simplifications reducing the number of hyperparameters :
• First, it is not interesting to improve the accuracy of the
predicted variations in zones A and B. Indeed, all predic-
tions belonging to these zones are clinically sufficiently
accurate. Thus, we can set ra = rb = 0.
• From the perspective of the possible maximization of the
AP rate, BE and EP predictions can be seen as equally
important. This allows us to set most of the C, D and
E zones to the same value. Moreover, the coherence
factor c alone allows us to weight the importance we give
between the accuracy of the predictions and the accuracy
of predicted variations. Thus, we can decide to set all
these weights to 1.
• Only the hypoglycemic P-EGA regions D and E (PuD and
PuE) require a special treatment in order to increase the
importance of samples in the hypoglycemic region. We
denote the weight associated with these areas by phypo.
The Equation 2 summarizes these design simplifications,
allowing the gcMSE cost function to have only 3 hyperparam-
eters: pab, phypo, and c. The choice of these hyperparameters
depends on both the learning objectives and the experimental
conditions. The coherence factor c must be chosen depending
on the importance of the cost function MSE(∆g,∆gˆ) com-
pared to the MSE(g, gˆ). The choice of the coefficient phypo
must be made according to the size of the datasets. When few
hypoglycemic samples are available, it is possible to give a
value of phypo > 1. As for pab, it represents the precision
constraint we give during training. The lower its value, the
more the training of the model focuses on improving its clinical
acceptability at the expense of its accuracy.
P (g, gˆ) =

pab, si {g, gˆ} ∈ {PA, PB}
phypo, si {g, gˆ} ∈ {PuD, PuE}
1, else
(2a)
and,
R(∆g,∆gˆ) =
{
0, si {∆g,∆gˆ} ∈ {RA, RB}
1, else
(2b)
D. Progressive Improvement of the Clinical Acceptability
In order to be able to use the gcMSE cost function, we
need to formulate the learning objective, and in particular
the relative importance of improving the clinical acceptability.
Indeed, as shown in the work of Del Favero et al., an
improvement in the clinical acceptability is often matched by
a deterioration in the statistical accuracy [14].
Research in the field of multi-objective optimization (MOO)
highlights the need of using selection criteria, which can take
the form of a weighting between the different objectives, or
thresholds for the different objectives [20]. Even though there
is no standard clinical criterion for glucose prediction models
today, we propose to project ourselves by assuming their exis-
tence. These clinical criteria could take the form of minimum
thresholds in AP and/or maximum thresholds in EP following
the CG-EGA (e.g., minimum 95% of predictions obtaining the
AP score in to CG-EGA). Our learning objective in this case
would be to maximize the accuracy of the predictions while
meeting the clinical criteria.
To achieve this goal, we need to test a large number
of different model architectures (hyperparameters), each test
involving the training of a neural network. This training is
very expensive in the context of deep learning. Therefore,
an efficient training methodology must be used in order to
reach the optimal solution. The methodologies generally used
to answer multi-objective optimization problems are based on
genetic methods (such as NSGA-II [21]). Although faster than
a simple grid search, these algorithms involve randomness
in the changes made to the different tests slowing down the
convergence.
In order to circumvent this problem, we propose the progres-
sive improvement of clinical acceptability (PICA) algorithm.
Starting from a solution that maximizes the model’s accuracy
without taking into account its clinical acceptability, the con-
straints on the precision are gradually relaxed in favor of its
clinical acceptability. This has the consequence of gradually
degrading the statistical accuracy of the model, a degradation
that is accompanied by a progressive improvement in clinical
acceptability.
Algorithm 1: Progressive Improvement of the Clinical
Acceptability (PICA)
Data: clinical criteria C, model M, update coefficient α,
smoothing coefficient β
Result: Model maximizing the accuracy while respecting
the clinical criteria C or −1
1 i← 0
2 M0 ← train(MSE)
3 g0, gˆ0 ← predict(M0)
4 gˆ∗0 ← smooth(gˆ0, β)
5 while C(Mi) = False et MASE(gi, gˆ
∗
i ) < 1 do
6 i← i+ 1
7 gcMSEi ← gcMSE avec pab ← αi−1
8 Mi ← finetune(M0, cMSEi)
9 gi, gˆi ← predict(Mi)
10 gˆ∗i ← smooth(gˆi, β)
11 if MASE(gi, gˆ
∗
i ) < 1 then
12 return Mi
13 else
14 return −1
The Algorithm 1 gives a description of the steps of the PICA
algorithm. The updating law of the weights pab, representing
the constraints in the statistical accuracy, is to be chosen
according to the experimental conditions. In this study, we
use the law defined by the Equation 3 (with α ∈ [0, 1] being
the speed of the relaxation of the accuracy constraints). As
for the MASE metric (mean absolute scaled error, proposed
by Hyndman et al. [22], see Equation 4), it is used as a
stopping criterion when clinical criteria are not achievable. The
6algorithm stops when the MASE exceeds 1, meaning that a
naïve prediction model (whose prediction is equal to the last
known observation) is more accurate than the present model.
Finally, we use an exponential smoothing of the predictions.
This smoothing allows to attenuate the important fluctuations
of the predictions in the first steps of the algorithm. By being
small, it allows a significant gain in clinical acceptability, in
return for a minimal loss of accuracy. For more details on the
exponential smoothing of the predictions, we invite the reader
to refer to the post-processing steps in Section III-C.
pab = α
i−1 (3)
MASE(g, gˆ, PH) =
1
N ·
∑N
n=1 |gn − gˆn|
1
N−PH ·
∑N
n=PH |gn − gn−PH |
(4)
The PICA algorithm avoids unnecessary iterations, each
iteration bringing the model closer and closer to its goal.
Moreover, instead of being trained from its initial state, the
model is refined from the first model, trained with the standard
MSE. This refinement requires much less iteration than a
full training, and thus allows the algorithm to run faster.
Another approach would have been to refine the model from
the previous iteration instead. However, in practice, we were
confronted with a local optimum problem, preventing the
model from finding a better solution after updating the cost
function.
III. METHODS
In this section, we present the whole methodology that
has been followed for the evaluation of the proposed losses
and the PICA algorithm. First, we present the experimental
datasets and their preprocessing. Then, we provide details
about the post-processing of the predictions and the models’
evaluation. Finally, we describe the different models with their
implementation.
We have made the whole implementation of the data pipeline
available in a GitHub repository [18].
A. Experimental Data
In this study, we used two datasets made of several diabetic
patients: the IDIAB dataset and the OhioT1DM dataset. While
the IDIAB has been collected by ourselves between 2018
and 2019 after the approval by the French ethical commitee
(ID RCB 2018-A00312-53), the OhioT1DM has recently been
released by Marling et al. [17].
1) IDIAB Dataset (I): The IDIAB dataset is made of 6
type-2 diabetic patients (5F/1M, age 56.5 ± 9.14 years old,
BMI 33.52 ± 4.17 kg/m2). The patients had been monitored
for 31.17 ± 1.86 days in free-living conditions. We collected
glucose values (in mg/dL) by using FreeStyle Libre continuous
glucose monitoring devices (Abbott Diabetes Care). As for
carbohydrate (CHO) intakes (g) and insulin infusion values
(unit), they have been manually recorded with the mySugr
coaching application for diabetes.
2) OhioT1DM Dataset (O): The OhioT1DM is made of
data coming from 6 type-1 diabetic patients (2M/4F, age
between 40 and 60 years old, BMI not disclosed) that had
been monitored for 8 weeks in free living conditions. For more
information concerning the experimental system, we redirect
the reader to [17]. We restrict ourselves to the glucose values,
the insulin infusions, and the CHO intakes to remain consistent
with IDIAB data.
B. Preprocessing
The preprocessing stage aims at preparing the data for their
use in the training and the evaluation of the models. It is made
of several steps depicted by Figure 3 and described in the
following paragraphs.
1) Cleaning: The glucose time-series from the IDIAB
dataset possess several erroneous values. These values are
characterized by peaks lasting only one sample. We decided to
remove these samples from the data as keeping them would be
hurtful for the training as well for the evaluation of the models.
Instead of removing them by hand, we used an automated
methodology proposed in our previous work [16]. A sample
is flagged as erroneous if the surrounding rates of change are
incoherent with the typical distribution of rates of change, and
if they are of opposite signs.
2) Samples Creation: The two datasets have been resam-
pled to a sample every 5 minutes which is the sampling
frequency of the OhioT1DM glucose signal. While we took
the mean of the glucose signals, the CHO and insulin values
have been accumulated.
The input samples have been obtained by using a sliding
window of length H of 3 hours (36 samples) on the three
signals. The prediction objective is, for each sample, the
glucose value 30 minutes (6 samples) in the future (prediciton
horizon, PH, of 30 minutes).
3) Recovering Missing Data: Both datasets contain numer-
ous missing values coming either from sensor or human errors.
Moreover, contrary to the OhioT1DM dataset, the upsampling
of the IDIAB glucose signal (from 15 minutes to 5 minutes)
has introduced a lot of missing values as well. We can
artificially recover some of them by following the following
strategy for every sample:
1) linearly interpolate the glucose history when the missing
value is surrounded by two known glucose values;
2) extrapolate linearly in the opposite case, usually when
the missing glucose value is the most recent data;
3) discard samples when the ground truth yt+PH is not
known to prevent training and testing on artificial data.
4) Splitting: The datasets are split into training, validation
and testing sets. While the testing set is used for the final evalu-
ation of the models, the validation is used as a prior evaluation
for the optimization of the models’ hyperparameters.
The testing set is made of the last 10 days for the
OhioT1DM dataset and of the last 5 days for the IDIAB
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Fig. 3: Preprocessing of the data.
dataset, the latter being around two times smaller. The re-
maining days have been split into training and validation sets
following an 80%/20% distribution with 5 permutations.
5) Feature Scaling: Finally, the samples have been stan-
dardized (zero mean and unit variance) w.r.t. their training set.
C. Post-processing and Evaluation
The evaluation of the predictive models is done following
the steps described by Figure 4. In this study, we focus models
that are personalized to the patient and that predict future
glucose values with a 30-minute prediction horizon. Before
evaluating the predictions, we follow two mandatory post-
processing steps. First, we rescale the predictions to their
original scale (see the features scaling preprocessing step).
Then, we reconstruct the prediction time-series by reordering
the predictions. In addition, the predictions made by the models
can be smoothed, as it is done in the PICA algorithm.
1) Exponential Smoothing: The PICA algorithm involves
the smoothing of the predictions at each iteration. The ob-
jective of this smoothing is to reduce excessive fluctuations
in the predicted glucose signal. These oscillations are not
representative of actual glucose variations and are therefore
dangerous for the patient.
We chose the exponential smoothing technique rather than
the moving average technique because it gives more weight to
recent predictions. Exponential smoothing can be defined as
recursive, with each value of the smoothed signal being equal
to a weighting between the value of the original signal and the
previous value of the smoothed signal (see Equation 5, where
gˆ∗t represents the smoothed value of the glucose prediction gˆt
and β the smoothing coefficient) [23].
gˆ∗t =
{
gˆ0, if t = 0
β · gˆt + (1− β) · gˆ∗t−1, else
(5)
The higher β is, the stronger is the weight given to the
original signal, and the less smooth the signal is. The choice
of the β smoothing coefficient in [0, 1] must be made carefully.
Indeed, too aggressive smoothing will result in a temporal shift
of the signal. In the context of glucose prediction, this will
greatly reduce the accuracy of the model, and therefore its
usefulness for the patient.
To our knowledge, although common in signal processing
(e.g., power consumption prediction [24]), no post-processing
smoothing has been done in the literature of glucose prediction.
We can nevertheless note the occasional use of low-pass filters
(which act similarly to the exponential smoothing technique)
on the input signal [3], [25].
D. Metrics
To evaluate the models we use four different metrics: the
RMSE, the MAPE, the MASE and the CG-EGA. For each
metric, the performances are averaged over the 5 test subsets
of each patient linked to a 5-fold cross-validation on the
training/validation permutations. They are then also averaged
on all the patients from the same dataset. Both the RMSE,
MAPE and MASE metrics give a complementary measure of
the accuracy of the prediction. While the RMSE is closely
related to the prediction scale, the MAPE is scale independent
and is expressed in percentage. As for the MASE, it measures
the average usefulness of the predictions compared to naïve
predictions (predictions equal to the last known observations).
The MASE is computed following Equation 4, presented in the
previous section. On the other hand, the CG-EGA measures
the clinical acceptability of the prediction by analyzing the
clinical accuracy as well as the coherence between successive
predictions. In the end, the CG-EGA classifies a prediction
either as an accurate prediction (AP), a benign error (BE), or
an erroneous prediction (EP). A high AP rate and a low EP
rate are necessary for a model to be clinically acceptable. The
rates can be either averaged over all the test samples, or for the
samples within a specific glycemic region (i.e., hypoglycemia,
euglycemia and hyperglycemia).
E. Glucose Predictive Models
The objective of the study is to improve the clinical ac-
ceptability of deep models. To this end, we first proposed a
new cost function cMSE which penalizes the model during its
training not only on prediction errors but also on predicted
variation errors. We then proposed the gcMSE, which is
the cMSE customized to glucose prediction. In particular, it
introduces weighting coefficients based on the CG-EGA to
enhance the clinical acceptability of the model. Finally, we
proposed the PICA algorithm that allows to progressively
improve the clinical acceptability of the models through the
use of the gcMSE function. The models that we present here
aim at evaluating these different proposals.
We use as reference models the Support Vector Regression
model (SVR) and Long Short-Term Memory recurrent neural
network (LSTM) from the GLYFE benchmark study [26]. As
the preprocessing steps are identical in the two studies, the
results are fully comparable. The SVR and LSTM models
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Fig. 4: Post-processing and evaluation of the predictions.
represent, respectively, the best model and the best deep model
in this benchmark.
First, to analyze the potential improvement of the clinical
acceptability through the cMSE and gcMSE cost functions, we
can evaluate the pcLSTM and gpcLSTM models respectively.
These two models are based on a two-output LSTM archi-
tecture, which, apart from the presence of the two outputs,
is identical to the LSTM model of the GLYFE benchmark
study. They are respectively trained to minimize the cMSE
and gcMSE loss functions with a coherence factor c set to 8
for the IDIAB dataset and 2 for the OhioT1DM dataset. This
difference between the two sets is explained by a MSE of
the predicted variations being approximately 4 times greater
for the OhioT1DM dataset. As for the coefficients pab and
phypo of the gcMSE, we set them to 1 and 10 respectively.
These coefficients are identical to those from the first iteration
of the PICA algorithm. In addition, we propose to evaluate
an additional variant of the gcMSE whose coefficient pab
is set to 0. This model, denoted gpcLSTMCA, is a model
that aims at maximizing the clinical acceptability, without
taking into account the precision of the model beyond clinical
acceptability needs.
The PICA algorithm uses the exponential smoothing tech-
nique to stabilize successive predictions. In order to fully eval-
uate the impact of the cost functions and the PICA algorithm,
we use the exponential smoothing technique on all the models
presented in this study. The smoothed variant of each model is
represented by a superscript asterisk (e.g., LSTM∗, pcLSTM∗,
gpcLSTM∗CA). All these models use a smoothing coefficient of
0.85, as it degrades only slightly the accuracy of the predicted
signal.
The PICA algorithm makes a compromise between the
gpcLSTM∗ and gpcLSTM∗CA models. The emphasis on clin-
ical acceptability of this compromise is progressive over
the iterations of the algorithm. However, the precision con-
straint, through the coefficient pab is never equal to 0 (model
gpcLSTM∗CA), because such a model has a precision far too
low to be useful for the diabetic patient. This is why the PICA
algorithm stops when the MASE exceeds the value of 1 on
the validation set. We represent by the model gpcLSTM∗PICA
the results obtained when the PICA algorithm stops. These
results present the upper bounds of clinical acceptability while
maintaining a useful accuracy. In the PICA algorithm, we use
the coefficient pab update law presented by Equation 3. It
involves the coefficient α, the rate at which the constraint in
accuracy is relaxed, which has been set to 0.9 in this study. A
higher coefficient gives better control over the final trade-off,
in return for a slower execution time (more iterations before
convergence). The PICA algorithm uses exponential smoothing
on the model’s predictions to increase the stability of the
predicted signal. The smoothing coefficient β, as for all the
smoothed variants of the other models, it was fixed at 0.85.
IV. EXPERIMENTAL RESULTS
A. Presentation of the Experimental Results
In this section we present the experimental results of this
study. These results are represented in the form of two tables:
Table II and III. While Table II describes the general results
of the different models in terms of RMSE, MAPE, MASE and
general CG-EGA, Table III gives a more detailed description,
by region, of the CG-EGA.
Within our two reference models, SVR and LSTM, the SVR
model is the model with the best clinical acceptability (general
or regional CG-EGA) for comparable accuracy. In particular,
the SVR model has one of the best clinical acceptability in
the hypoglycemia region (69.39% and 49.71% AP for the
IDIAB and OhioT1DM datasets respectively). The exponential
smoothing improves the clinical acceptability of the SVR
model (SVR* model) by -12.79%1 of AP rate for an increase
of +0.90% in RMSE (decrease in accuracy). The LSTM*
model is subject to similar changes with -11.44% AP and
+0.98% RMSE. Table III shows that these improvements in
clinical acceptability occur in the euglycemia or hyperglycemia
regions, and not in the hypoglycemia region (small decrease
in AP).
The pcLSTM model and its smoothed variant pcLSTM*,
using the cMSE cost function as well as the two-output
architecture of the LSTM network, are showed to improve
the clinical acceptability while deteriorating the accuracy. In
particular, the pcLSTM* model compared to the LSTM* model
has -24.18% AP, and +8.95% RMSE. The improvement in
clinical acceptability is greater for the OhioT1DM dataset
(-32.19% AP) than for the IDIAB dataset (-16.16% AP).
For a comparable decrease in accuracy, the OhioT1DM set
benefits more from the cMSE cost function than the IDIAB
set. Moreover, the pcLSTM* model has among the best clinical
acceptability scores in the euglycemia and hyperglycemia
regions. However, in comparison with the LSTM or LSTM*
models, the clinical acceptability in the hypoglycemia region
is deteriorated, especially for the OhioT1DM dataset.
1Here we represent the decrease, in %, of what is metrically improvable.
For the AP, which has a maximum of 100%, the ratio of change is calculated
as (100−AP1)/(100−AP2).
9TABLE II: Mean (with standard deviation) of statistical accuracy (RMSE, MAPE, and MASE) and general clinical acceptability
(CG-EGA) for a prediction horizon of 30 minutes and for the IDIAB and OhioT1DM datasets.
Model RMSE MAPE MASE CG-EGA (general)AP BE EP
IDIAB Dataset
SVR 20.32 (6.02) 8.66 (0.44) 0.85 (0.15) 92.69 (2.81) 5.34 (2.06) 1.97 (1.23)
LSTM 19.85 (6.00) 9.04 (1.11) 0.85 (0.10) 92.20 (2.99) 5.05 (1.71) 2.76 (1.82)
SVR* 20.67 (6.20) 8.86 (0.44) 0.88 (0.15) 93.62 (2.57) 4.47 (1.69) 1.92 (1.35)
LSTM* 20.27 (6.30) 9.25 (1.21) 0.87 (0.09) 93.16 (3.13) 4.16 (1.75) 2.68 (2.00)
pcLSTM 21.89 (5.68) 10.28 (1.34) 0.96 (0.11) 94.04 (3.26) 3.20 (1.66) 2.76 (2.07)
pcLSTM* 22.63 (6.04) 10.64 (1.40) 1.00 (0.11) 94.24 (3.35) 2.94 (1.73) 2.82 (2.07)
gpcLSTM 21.21 (5.64) 9.35 (0.92) 0.91 (0.13) 94.03 (2.66) 3.91 (1.48) 2.06 (1.54)
gpcLSTM* 21.86 (5.94) 9.66 (0.95) 0.94 (0.13) 94.53 (2.84) 3.38 (1.55) 2.08 (1.57)
gpcLSTMCA 40.68 (11.20) 18.14 (5.55) 1.91 (0.55) 95.34 (2.76) 3.29 (2.56) 1.37 (0.91)
gpcLSTM*CA 41.15 (11.18) 18.36 (5.47) 1.93 (0.54) 95.35 (2.87) 3.20 (2.61) 1.45 (0.92)
gpcLSTM*PICA 24.03 (7.15) 10.43 (1.18) 1.03 (0.09) 95.00 (2.74) 3.38 (1.99) 1.61 (1.22)
OhioT1DM Dataset
SVR 20.15 (2.33) 9.12 (2.11) 0.85 (0.02) 83.35 (3.91) 12.38 (2.83) 4.28 (1.83)
LSTM 20.46 (2.08) 9.24 (2.10) 0.86 (0.02) 80.03 (4.17) 14.83 (2.88) 5.14 (2.11)
SVR* 20.17 (2.30) 9.18 (2.12) 0.85 (0.02) 85.00 (4.05) 10.97 (2.72) 4.03 (1.90)
LSTM* 20.43 (2.03) 9.26 (2.10) 0.86 (0.02) 82.14 (3.94) 13.06 (2.51) 4.81 (2.04)
pcLSTM 21.53 (2.23) 10.07 (2.32) 0.93 (0.03) 87.45 (3.76) 8.46 (2.05) 4.09 (2.14)
pcLSTM* 21.71 (2.22) 10.19 (2.35) 0.94 (0.03) 87.89 (3.61) 8.15 (1.94) 3.96 (2.12)
gpcLSTM 21.66 (2.69) 9.65 (2.14) 0.92 (0.03) 86.97 (3.63) 9.50 (2.52) 3.53 (1.48)
gpcLSTM* 21.82 (2.69) 9.76 (2.16) 0.93 (0.03) 87.59 (3.45) 9.01 (2.31) 3.41 (1.49)
gpcLSTMCA 47.70 (6.31) 22.43 (2.76) 2.37 (0.53) 90.46 (2.85) 7.16 (1.66) 2.37 (1.28)
gpcLSTM*CA 47.82 (6.27) 22.47 (2.76) 2.37 (0.53) 90.51 (2.88) 7.12 (1.64) 2.37 (1.30)
gpcLSTM*PICA 23.50 (2.49) 10.46 (2.09) 1.01 (0.03) 88.72 (3.59) 8.20 (2.23) 3.08 (1.64)
TABLE III: Mean (with standard deviation) of per-region clinical acceptability (CG-EGA) for a prediction horizon of 30
minutes and for the IDIAB and OhioT1DM datasets.
Model
CG-EGA (per region)
Hypoglycemia Euglycemia Hyperglycemia
AP BE EP AP BE EP AP BE EP
IDIAB Dataset
SVR 69.39 (33.51) 0.35 (0.70) 30.27 (33.54) 95.17 (2.01) 4.33 (1.83) 0.50 (0.47) 89.51 (6.09) 7.43 (3.86) 3.06 (2.53)
LSTM 40.94 (30.73) 0.00 (0.00) 59.06 (30.73) 95.78 (1.48) 3.83 (1.55) 0.39 (0.38) 89.55 (5.60) 7.35 (3.21) 3.10 (2.45)
SVR* 66.37 (31.47) 0.17 (0.35) 33.45 (31.51) 96.13 (1.81) 3.49 (1.66) 0.39 (0.36) 90.61 (5.67) 6.60 (3.23) 2.79 (2.79)
LSTM* 37.99 (31.22) 0.00 (0.00) 62.01 (31.22) 96.71 (1.35) 2.95 (1.46) 0.33 (0.38) 91.02 (6.04) 6.18 (3.67) 2.80 (2.58)
pcLSTM 34.59 (29.27) 0.00 (0.00) 65.41 (29.27) 97.58 (0.90) 2.13 (0.82) 0.29 (0.20) 92.60 (5.81) 4.94 (3.18) 2.46 (2.80)
pcLSTM* 32.20 (27.83) 0.00 (0.00) 67.80 (27.83) 97.96 (0.98) 1.81 (0.91) 0.23 (0.11) 92.81 (6.25) 4.68 (3.48) 2.51 (2.85)
gpcLSTM 64.79 (24.95) 0.00 (0.00) 35.21 (24.95) 96.60 (1.11) 3.03 (0.99) 0.37 (0.26) 92.06 (5.12) 5.42 (2.83) 2.51 (2.46)
gpcLSTM* 61.87 (25.17) 0.00 (0.00) 38.13 (25.17) 97.23 (1.17) 2.46 (1.02) 0.31 (0.22) 92.65 (5.60) 4.85 (3.09) 2.50 (2.68)
gpcLSTMCA 87.95 (9.58) 1.71 (3.43) 10.34 (8.15) 97.37 (1.36) 2.12 (1.03) 0.51 (0.40) 92.17 (4.46) 5.11 (4.52) 2.72 (2.39)
gpcLSTM*CA 87.77 (9.53) 1.71 (3.43) 10.51 (8.13) 97.50 (1.32) 1.97 (0.97) 0.52 (0.44) 92.10 (4.69) 5.03 (4.70) 2.87 (2.33)
gpcLSTM*PICA 68.49 (27.85) 0.57 (1.14) 30.94 (28.22) 97.35 (1.18) 2.32 (1.08) 0.33 (0.15) 93.16 (4.84) 5.08 (3.53) 1.76 (1.49)
OhioT1DM Dataset
SVR 49.71 (18.75) 5.62 (4.02) 44.67 (18.70) 86.35 (4.24) 10.71 (3.26) 2.94 (1.23) 80.85 (3.24) 14.77 (3.01) 4.37 (1.84)
LSTM 38.37 (23.17) 3.97 (3.72) 57.67 (24.23) 83.78 (5.33) 12.70 (4.06) 3.52 (1.47) 76.86 (3.70) 17.87 (2.73) 5.27 (2.21)
SVR* 46.95 (21.11) 5.97 (4.05) 47.09 (21.65) 87.83 (4.22) 9.46 (3.21) 2.71 (1.22) 82.81 (3.43) 13.12 (2.98) 4.07 (2.00)
LSTM* 37.34 (23.50) 4.11 (4.15) 58.56 (24.17) 85.71 (4.83) 11.10 (3.58) 3.19 (1.37) 79.27 (3.55) 15.85 (2.40) 4.88 (2.24)
pcLSTM 25.28 (19.11) 3.64 (3.73) 71.08 (19.35) 90.79 (3.43) 6.93 (2.53) 2.28 (1.01) 85.78 (3.64) 10.83 (2.55) 3.40 (2.03)
pcLSTM* 23.82 (18.23) 3.72 (3.48) 72.45 (18.55) 91.20 (3.17) 6.67 (2.35) 2.13 (0.96) 86.33 (3.54) 10.44 (2.50) 3.23 (1.96)
gpcLSTM 53.66 (22.59) 4.34 (3.83) 42.00 (22.86) 89.39 (3.91) 7.99 (2.90) 2.63 (1.12) 84.61 (3.84) 11.79 (3.20) 3.61 (2.01)
gpcLSTM* 52.37 (22.06) 4.32 (3.15) 43.30 (22.42) 90.02 (3.69) 7.47 (2.77) 2.52 (1.04) 85.27 (3.69) 11.31 (2.95) 3.42 (2.02)
gpcLSTMCA 91.17 (8.50) 1.26 (2.08) 7.57 (8.01) 91.61 (2.03) 6.62 (1.39) 1.77 (0.74) 87.97 (5.00) 8.67 (2.64) 3.36 (2.63)
gpcLSTM*CA 91.02 (8.49) 1.21 (1.97) 7.77 (8.00) 91.71 (2.02) 6.55 (1.34) 1.75 (0.77) 87.95 (5.05) 8.69 (2.69) 3.36 (2.62)
gpcLSTM*PICA 61.30 (20.12) 2.92 (2.38) 35.79 (20.23) 90.84 (3.57) 7.04 (2.57) 2.11 (1.07) 86.48 (3.95) 10.07 (2.66) 3.45 (2.31)
The gpcLSTM and gpcLSTM* models, using the gcMSE cost function, cMSE customized to blood glucose prediction,
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show a degradation of the RMSE and an improvement of
the AP rate similar to the pcLSTM and pcLSTM* models.
However, the gpcLSTM and gpcLSTM* models have a lower
EP rate (-19.53% and -20.07% respectively), suggesting an
improved clinical acceptability. Table III shows that this im-
provement is mainly in the hypoglycemia region with much
lower EP rates.
The models gpcLSTMCA and gpcLSTM*CA use a gcMSE
function with the coefficient pab of 0. Thus, these models
focus only on improving the clinical acceptability. Not seeking
to improve the accuracy of predictions beyond the required
clinical accuracy (P-EGA Zone B), these models have a very
poor RMSE, MAPE and MASE. Nevertheless, they have the
best clinical acceptability, with the highest AP and the lowest
EP rates. The improvement is particularly important in the
hypoglycemic region, as can be seen in Table III.
The gpcLSTM*PICA model represents the latest iteration of
the PICA algorithm with a MASE on the validation set of
less than 1. This model is intended to maximize the clinical
acceptability, while having a reasonable accuracy (MASE less
than 1). Compared to the gpcLSTM*CA model, it has a slightly
lower clinical acceptability (but better than all other models,
thanks in particular to its low EP rate).
B. Discussion
The results show us that exponential smoothing reduces
the benign error (BE) rate in favor of a better AP rate, by
reducing the amplitude of the variations between successive
predictions. This improvement is valid for most of the mod-
els and has for counterpart a rather small decrease in the
general accuracy of the model. Thus, exponential smoothing,
used softly (coefficient β of 0.85) is an efficient method to
improve the stability of the prediction signal, making it safer
for the diabetic patient. However, it remains useless in the
hypoglycemia range where the majority of clinical prediction
errors are due to poor accuracy.
The effects of using the cMSE cost function on glucose
predictions are similar: successive glucose predictions are more
consistent with each other, resulting in a large reduction in the
BE rate. The effects are greater for the OhioT1DM dataset,
which sees its EP rate decrease at the same time. We can
explain this by a higher noise in the predicted glucose signal
of the OhioT1DM set, noise that comes from the initial glucose
signal. With its lower sampling frequency, the IDIAB glucose
signal manages to be less noisy in comparison. The cMSE
allows successive predictions to be made with a rate of change
that better reflects the actual rate of change and thus improves
its clinical acceptability. However, like exponential smoothing,
improvements in clinical acceptability are not generalized to
all glycemic regions. In particular, the hypoglycemic region
appears to suffer from the use of cMSE with an increase in its
EP rate, especially for the OhioT1DM dataset.
The gcMSE action is more focused on the decrease of the
EP rate, as shown by the models gpcLSTM, gpcLSTMCA,
gpcLSTM*PICA. In contrast with the exponential smoothing
technique and the cMSE cost function, the gcMSE improves all
glycemic regions, and in particular the hypoglycemic region.
Moreover, these improvements allow the LSTM neural net-
work to surpass, in clinical acceptability, the SVR model which
is the best model of the GLYFE benchmark study. Figure 5
allows us to appreciate the differences in the predictions of
the different models. First, we can see the large variations
and noise in the predicted glucose signal of the LSTM model.
These oscillations are reduced for the other models, becoming
closer to the observed glucose signal. However, when using the
cMSE cost function (pcLSTM* signal in purple), we witness
a large loss of accuracy in the hypoglycemia region (between
4:00 and 8:00 am). While the signal gpcLSTM*PICA shows to be
very close to the signal observed in the hypoglycemia region,
this is done at the cost of an overall loss in accuracy. Finally,
gpcLSTM*, is a compromise between the two.
Although we can conclude on the strength of using the
gcMSE cost function in the training of deep models predicting
future glucose levels in people with diabetes, the different
results show us that there are many possible tradeoffs be-
tween accuracy and clinical acceptability. The PICA algorithm
proposed in this study aims at selecting the best compromise
between accuracy and clinical acceptability based on selec-
tion criteria. Figure 6 gives a graphical representation of the
changes in MASE, general AP rate and general EP rate of the
models throughout the PICA algorithm for all the patients. As
previously discussed, there is no clinical criterion for glucose
predictive models yet, so the only criterion for stopping the
algorithm here was the MASE exceeding 1. The figure first
shows us that the number of iterations before stopping the
algorithm is variable from one dataset to another, and also
from one patient to another (25.0 ± 3.96 for the IDIAB
dataset, and 11.66 ± 5.06 for the OhioT1DM dataset). This
is explained first of all by the variable initial accuracy of
the different patients, some patients being easier to predict
than others (see iteration 0 on Figures 6a and 6b). As we
have observed through the analysis of Table II, the main
improvements in clinical acceptability are made at the first
iteration (iteration 1) of the algorithm when introducing the
gcMSE cost function and exponential smoothing. Nevertheless,
throughout the algorithm, the clinical acceptability gradually
improves at the expense of the accuracy. We can see that
the rate of deterioration and improvement is different from
one patient to another, showing the very high inter-patient
variability in the diabetic population.
Although there is currently no clinical criterion for glucose
prediction models, we can analyze the use of two hypothetical
criteria through Table IV: a minimum AP rate, and a maximum
EP rate. As expected, the harder the clinical criteria (higher
threshold and/or combination of criteria), the lower the number
of patients passing the clinical test. Only one patient in the
IDIAB dataset managed to have simultaneously more than
97% AP and less than 1% EP. In addition, we can note a
greater success of IDIAB patients on these clinical tests, com-
pared to OhioT1DM patients. As previously mentioned, these
differences in clinical performance are due to the difference
in experimental systems. While the final evaluation of the
OhioT1DM dataset is done every 5 minutes, it is done every
15 minutes for the IDIAB dataset. In addition, the glucose
signal of IDIAB patients is overall less noisy, and therefore
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Fig. 5: Predictions of the LSTM*, pcLSTM*, gpcLSTM* and gpcLSTM*PICA models for the patient 575 from the OhioT1DM
dataset for a given day.
more stable and easier to predict. Thus, for a future practical
use, the clinical criteria must be rigorously standardized.
Finally, we note that the MASE on the testing set (the one
reported in Tables II and III) is slightly higher than 1 (1.03
and 1.01 for the IDIAB and OhioT1DM datasets). Using such
a stopping criterion, we could have assumed that the final
MASE on the testing set would be less than 1, as it is the case
on the validation set. This happens because the test subset
is not fully representative of the validation subset. This is
due to the general small quantities of data in the datasets,
negatively impacting the representativeness of these subsets.
We also note that the standard deviation for the IDIAB dataset
is higher, showing that the final value of the MASE is highly
variable depending on the subject. Thus, the accuracy of the
PICA algorithm would be improved by using more data (which
would also improve the performance of the models in general).
V. CONCLUSION
In this study, we proposed a framework for the integration
of clinical criteria into the training of deep models. Clinical
criteria are often different from standard statistical metrics used
as loss functions. As a consequence the best model, given a
loss function used during its training, is not necessarily the
model with the best clinical acceptability. We address this
issue from the perspective of the challenging task of predicting
future glucose values of diabetic people.
In glucose prediction, the CG-EGA metric measures the
clinical acceptability of the predictions. In particular, it as-
TABLE IV: Number of patients within a given dataset that can
respect different clinical criteria (minimal AP rate or maximal
EP rate) through the PICA algorithm.
Clinical Criterion Dataset
AP (≥) EP (≤) IDIAB Ohio
80 - 6 6
90 - 6 3
95 - 4 0
97 - 3 0
- 7 6 6
- 5 6 4
- 3 6 3
- 1 4 0
80 7 6 6
90 5 6 3
95 3 4 0
97 1 2 0
sesses the safety of the predictions by looking at the prediction
accuracy and the predicted rate of change accuracy. Moreover,
the metric behaves differently for the different glycemic re-
gions, some errors being more dangerous than others without
being high amplitude errors. Starting from the cMSE loss
function we proposed in an earlier work of ours [16] that
penalizes the model during its training not only on prediction
errors but also on predicted variation errors, we proposed to
personalize the loss function to the glucose prediction task.
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Fig. 6: Evolution of the MASE and CG-EGA (AP and EP) metrics throughout the PICA algorithm for the IDIAB and OhioT1DM datasets.
Iterations 0 and 0* respectively represent the results of the model trained with the MSE cost function before and after smoothing the
predictions.
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Based on the CG-EGA, this personalization, called gcMSE,
weights the errors differently depending on the scores obtained
in the P-EGA and R-EGA grids. Finally, we proposed the
PICA algorithm to obtain the solution that maximizes the
accuracy of the model while at the same time respecting given
clinical criteria.
We evaluate the different proposed loss functions and the
PICA algorithm with two different diabetes datasets, the
IDIAB and the OhioT1DM dataset. First, we showed that
the cMSE loss function increase the coherence of successive
predictions, improving the clinical acceptability of the models.
However, this improvement comes at the cost of a decrease
in the accuracy of the model. Then, we showed that the
gcMSE further improves the clinical acceptability by reducing
the rate of life-threatening errors. Finally, we demonstrate
the usefulness of the PICA algorithm that help in choosing
the desired tradeoff between general accuracy and clinical
acceptability.
The analysis of different clinical criteria showed that not all
the patients were able to meet them easily. It depends on the
difficulty of the glucose prediction task of the patient, varying
from patient to patient, but also on the nature of dataset, and
in particular on the devices used for the data collection. These
factors would need to be taken into account when creating
future regulations for the use of such models by diabetic
patients.
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